ROS1 and anaplastic large cell lymphoma: Crizotinib has been approved by the FDA to treat patients with ALK- or ROS1-positive NSCLC and pediatric patients with relapsed or refractory ALK-positive systemic anaplastic large-cell lymphoma (ALCL) [86,87].